Upper Respiratory Tract InfectionNCT06140446
Effect of eHealth on AB Use of Children With Acute, Uncomplicated URTIs
A study testing FeverApp and DMT App in people with Upper Respiratory Tract Infection, run by Max Nieuwdorp at 1 site in Netherlands.
Trial summary
The goal of this clinical trial is to test the effectiveness of two self-care eHealth applications in parents of children with uncomplicated upper respiratory tract infections (URTIs). Read more about this study
- Who is it for?
- Ages 3 months to 12 years
- Conditions the study is for
- Upper Respiratory Tract Infection
- What is being tested?
- FeverApp and DMT App
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 411 participants
- Where
- 1 siteNetherlands
- Study dates
- Dec 2023to May 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 months to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Having a child aged 0-12 years old
- Master the Dutch language
- Having called the GP for their child aged 0-12 years having:
- Fever (≥38 °C) AND
- At least one of the following symptoms:
- Acute cough
Show all 12Show fewer
- Sore throat
- Earache/runny ear
- Nasal congestion/runny nose
- Headache
- Being screened by a triage specialist (GP practice assistant) and not being indicated for a GP/NP/PA visit
- Not being included in the trial before
Who cannot join
- The current URTI complaints of the child already exist longer than 2 weeks
- The child who has a URTI
- is younger than 3 months old
- has asthma or another chronic or severe illness
- has a history of pneumonia
- has a history of complications or hospitalization from a previous URTI
Show all 9Show fewer
- has Down Syndrome
- has a less functioning immune system
- The parent being very worried
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effect of Two eHealth Applications on Antibiotic Use for Acute, Uncomplicated Upper Respiratory Tract Infections in Children: a Randomized Controlled Trial Among Parents in Dutch General Practice
The goal of this clinical trial is to test the effectiveness of two self-care eHealth applications in parents of children with uncomplicated upper respiratory tract infections (URTIs).
The main question it aims to answer is:
Read more
- What is the effect of a self-management FeverApp and a self-care herbal medicine decision making tool (DMT) on reducing antibiotic use for acute, uncomplicated URTIs, among children in Dutch general practice?
Participants will:
- Complete an online questionnaire at baseline
- Use a self-care eHealth application for ten days (in the intervention groups)
- Report symptom severity of the URTI of their child online at day 2, 5 an 7
- Complete an online follow-up questionnaire at day 10
- Collect two stool samples of their child at baseline and at day 10
Researchers will compare three groups to see if the Apps have an effect on recovery time and complications from URTIs, AB use, frequency of GP visits, and diversity of the gut microbiome:
- Parents that will use an evidence based fever app additional to standard advices of their GP
- Parents that will use an evidence based herbal medicine DMT additional to standard advices of their GP
- A control group of parents who will receive just standard advices from their GP,
Read the detailed description
Rationale:
Antimicrobial resistance (AMR) is a complex and growing international public health problem with important consequences as increased mortality and high economic impact. Less inappropriate antibiotic (AB) prescription is one of the global strategies to reduce AMR. In primary care most inappropriate AB prescriptions are for acute, uncomplicated respiratory tract infections (URTIs). URTIs are among the most frequently seen complaints among children in general practice. ABs are only indicated for URTis in case of complications. Nevertheless, they are still often prescribed for uncomplicated cases. A reason for this could be worried parents parents requesting for an AB prescription for their child. In Dutch primary care, ABs can be prescribed by general practitioners (GPs), nurse practitioners (NPs) and physician assistants (PAs). Besides AMR, ABs can cause damage to the gut microbiome. Adequate fever (self) management and safe use of effective (self-care) herbal medicine (HM) are both expected to reduce AB use in mild, acute uncomplicated URTIs. Therefore, a (self-management) FeverApp and a (self-care) herbal medicine decision making tool (DMT App) were developed for parents in general practice.
Objectives:
The primary objective of this study is to investigate the effect of a self-management FeverApp and a self-care DMT App on reducing antibiotic use for acute, uncomplicated URTIs, among children in Dutch general practice. Secondary objectives are to examine (1) amount of apps-related complications and recovery time from acute, uncomplicated URTIs in comparison to standard GP advices, (2) the effect of apps use on reducing the number of GP practice visits and telephone consultations for acute, uncomplicated URTIs, and (3) the effects of apps use (reducing AB use) on diversity of the gut microbiome.
Study design:
The study design is a Randomized Controlled Trial (RCT) in six GP practices. There will be three study groups: (1) a group of parents who will be advised to use the FeverApp additional to advices from their GP practice, (2) a group of parents who will be advised to use the self-care DMT App additional to advices from their GP practice, and (3) a control group of parents who will only receive advices from their GP practice. Recruitment of parents will be done by the GP practice assistants of the participating practices, and selection and inclusion will be carried out by a research assistant from University of Applied Sciences Leiden (UAS Leiden). Randomization over the conditions will be done at random by the research assistant. This will result in parents assigned to either the Fever App group, the DMT App group or the control group. All included parents will, after receiving the participant information, fill out a baseline online questionnaire (including digital informed consent), and will collect a baseline stool sample of their child and save it in the freezer (T0). After that, parents in the intervention groups download and use the app they were assigned to, and all parents report (severity of) URTI symptoms of their child online at 2, 5 and 7 days (T1, T2 and T3) in an online form. Ten days after T0, all parents fill out a follow-up questionnaire, collect a second stool sample from their child, and save it in their own -20 degrees Celsius freezer (T4). At the end of the study, all of the stool samples will be picked up at home by research assistants from UAS Leiden, and will be transferred to Amsterdam University Medical Centre for the laboratory gut microbiome analysis.
Benefits, burden and risks:
The benefit of participating in the study, is that parents in the intervention groups will get extra support by means of the apps, on top of the advices that will be provided by the GP practice. For the control group there is no real benefit, besides contributing to less AB use among children in the future. The burden of this study lies in the fact that parents who participate, will have to fill out two online questionnaires within two weeks, report symptom severity online at two more timepoints, and will have to collect a stool sample of their child twice and save it in the freezer. Parents in the intervention groups will get the advice to download and use one of the two investigated apps. It will be their own decision to actually do this or not.
Participating in the study is safe, because only parents of children with mild, acute, uncomplicated URTIs will be involved. Furthermore, advices/care by the GP practice will be continued for all patients in the study, and the advices in the (self-management) fever app are in line with national fever guidelines. The only difference is that, based on the most recent insights on fever, the app encourages to keep the child warm in the first phase of fever. With regards to safety of the (self-care) DMT App, adverse events due to HM are rare. Moreover, the herbs that are advised on in the app are freely available (without prescription) in drugstores and pharmacies in the Netherlands. Therefore, using the (self-care) DMT App will make things safer rather than less safe, because parents in the HM group will get a trustworthy advice based on scientific evidence and safety regulations, instead of buying herbal medicine without an evidence-based decision-making tool (DMT) like they would normally do.
All participating parents will be advised to always go to the national website with GP advices in case of doubts about the health status of their child, and to call their GP practice, the ED (emergency department) or 112 in case of alarm symptoms. Furthermore, all parents are told to report complications from the URTI and/or adverse events (such as hospitalization) to the researchers. In case of complications or adverse events, they will be will go back to just receiving advices/care from their GP/NP/PA. Participating parents will use the apps in a test account, so no data will be collected by the apps. Also, the online questionnaires they fill out are anonymous, so the privacy of parents who participate is secured. Finally, parents can leave the study at any moment and go back to just receiving advices from their GP practice. There is no relation between (parents in) the different study groups.
- Conditions
- Upper Respiratory Tract Infection
- Being tested
- FeverApp, DMT App
- Keywords
- eHealth, Antibiotics, Gut microbiome, General practice
- Medical subject headings
- Respiratory Tract Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FeverAppDevice
The (self-management) FeverApp contains evidence-based information about fever and how to deal with it, tailored (phase-oriented) fever advices, and the option to monitor the health status of the child during a fever episode. All information and advices are based on the clinical expertise of paediatricians and the most recent international literature on fever, and complement the Dutch national fever guidelines. It is expected that by letting the body fight the infection on its own in a safe way, less ABs are needed, and the immune system will get stronger leading to less future infections as well.
DMT AppDevice
The (self-care) DMT App is a decision making tool (DMT) that can be used by parents to choose a safe and effective herbal medicine (HM) product to reduce symptoms of mild, acute uncomplicated URTIs in their child. The advices that the DMT App provides, are based on a systematic review (SR) of SRs on effectiveness of HM for URTIs, a SR on working mechanisms of the most promising herbs, a prescription rates study of HM for URTIs in 6 European countries, and current EMA status of the included herbs. No prescription from a doctor is needed for these products.
| Study group | Role | What they receive |
|---|---|---|
| FeverApp group | Experimental | Use af a self-care FeverApp (containing fever advices and a monitoring function for their child with an uncomplicated URTI), additional to standard advices of the GP. Receives: Device: FeverApp |
| DMT group | Experimental | Use of a self-care decision making tool (to choose a herbal medicinal product for their child with an uncomplicated URTI), additional to standard advices from their GP. Receives: Device: DMT App |
| Control group | No intervention | Just standard advices from the GP for their child with an uncomplicated URTI. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Antibiotic use (yes/no)
Antibiotic use of the child in the current URTI episode
Measured: Self-reported10 days after inclusion in the study
Secondary outcomes (7)
Normal recovery time from URTI
Recovery of the URTI within 7 days (based on the clinical expertise of GPs)
Measured: Self-reported 10 days after inclusion in the study
Adverse events/complications
Adverse events/complications from current URTI
Measured: Self-reported 10 days after inclusion in the study
GP visits
Number of follow-up GP/NP/PA visits for the current URTI episode
Measured: Self-reported 10 days after inclusion in the study
Telephone consultations
Number of follow-up telephone consultations for the current URTI episode of the child
Measured: Self-reported 10 days after inclusion in the study
Gut microbiome diversity
Change in diversity of the gut microbiome (by means of stool samples)
Measured: At baseline (inclusion) AND 10 days after inclusion in the study
AB type
Type of AB used in current URTI episode
Measured: Self-reported at 10 days after inclusion in the study
AB dosage
AB dosage used in current URTI episode
Measured: Self-reported at 10 days after inclusion in the study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2023
- Study startDec 2023 (estimated)
- Primary completionMay 2024 (estimated)
- Study completionMay 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Upper Respiratory Tract InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- RCT
- Masking
- None (open label)
- Enrolment
- 411 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Max Nieuwdorp
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Max Nieuwdorp, Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)
- Investigators
- Max Nieuwdorp, PhD, Study director, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06140446
- Sponsor's protocol ID
- NW2023-49
- Status last verified
- Nov 2023
- First submitted
- 14 Nov 2023
- Last updated
- 21 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Belt-van Zoen E, van Steenbergen N, Veldman L, Nieuwdorp M, Baars EW. Evaluating the effects of two parental self-management eHealth applications on antibiotic use, number of primary care visits and gut microbiota of febrile Dutch children with acute, uncomplicated upper respiratory tract infections: a study protocol for a randomised controlled trial. BMJ Open. 2025 Dec 19;15(12):e101463. doi: 10.1136/bmjopen-2025-101463.
PubMed 41419287
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Two eHealth Applications on Antibiotic Use for Acute, Uncomplicated Upper Respiratory Tract Infections in Children: a Randomized Controlled Trial Among Parents in Dutch General Practice
- ClinicalTrials.gov ID
- NCT06140446
- Acronym / sponsor ID
- NW2023-49
- Conditions
- Upper Respiratory Tract Infection
- Keywords
- eHealth, Antibiotics, Gut microbiome, General practice
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 411 participants (estimated)
- Lead sponsor
- Max NieuwdorpUniversity, hospital or other
- Study start
- Dec 2023 (estimated)
- Primary completion
- May 2024 (estimated)
- Study completion
- May 2024 (estimated)
- First posted
- 20 Nov 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to test the effectiveness of two self-care eHealth applications in parents of children with uncomplicated upper respiratory tract infections (URTIs).
The main question it aims to answer is:
- What is the effect of a self-management FeverApp and a self-care herbal medicine decision making tool (DMT) on reducing antibiotic use for acute, uncomplicated URTIs, among children in Dutch general practice?
Participants will:
- Complete an online questionnaire at baseline
- Use a self-care eHealth application for ten days (in the intervention groups)
- Report symptom severity of the URTI of their child online at day 2, 5 an 7
- Complete an online follow-up questionnaire at day 10
- Collect two stool samples of their child at baseline and at day 10
Researchers will compare three groups to see if the Apps have an effect on recovery time and complications from URTIs, AB use, frequency of GP visits, and diversity of the gut microbiome:
- Parents that will use an evidence based fever app additional to standard advices of their GP
- Parents that will use an evidence based herbal medicine DMT additional to standard advices of their GP
- A control group of parents who will receive just standard advices from their GP,
Detailed description
Rationale:
Antimicrobial resistance (AMR) is a complex and growing international public health problem with important consequences as increased mortality and high economic impact. Less inappropriate antibiotic (AB) prescription is one of the global strategies to reduce AMR. In primary care most inappropriate AB prescriptions are for acute, uncomplicated respiratory tract infections (URTIs). URTIs are among the most frequently seen complaints among children in general practice. ABs are only indicated for URTis in case of complications. Nevertheless, they are still often prescribed for uncomplicated cases. A reason for this could be worried parents parents requesting for an AB prescription for their child. In Dutch primary care, ABs can be prescribed by general practitioners (GPs), nurse practitioners (NPs) and physician assistants (PAs). Besides AMR, ABs can cause damage to the gut microbiome. Adequate fever (self) management and safe use of effective (self-care) herbal medicine (HM) are both expected to reduce AB use in mild, acute uncomplicated URTIs. Therefore, a (self-management) FeverApp and a (self-care) herbal medicine decision making tool (DMT App) were developed for parents in general practice.
Objectives:
The primary objective of this study is to investigate the effect of a self-management FeverApp and a self-care DMT App on reducing antibiotic use for acute, uncomplicated URTIs, among children in Dutch general practice. Secondary objectives are to examine (1) amount of apps-related complications and recovery time from acute, uncomplicated URTIs in comparison to standard GP advices, (2) the effect of apps use on reducing the number of GP practice visits and telephone consultations for acute, uncomplicated URTIs, and (3) the effects of apps use (reducing AB use) on diversity of the gut microbiome.
Study design:
The study design is a Randomized Controlled Trial (RCT) in six GP practices. There will be three study groups: (1) a group of parents who will be advised to use the FeverApp additional to advices from their GP practice, (2) a group of parents who will be advised to use the self-care DMT App additional to advices from their GP practice, and (3) a control group of parents who will only receive advices from their GP practice. Recruitment of parents will be done by the GP practice assistants of the participating practices, and selection and inclusion will be carried out by a research assistant from University of Applied Sciences Leiden (UAS Leiden). Randomization over the conditions will be done at random by the research assistant. This will result in parents assigned to either the Fever App group, the DMT App group or the control group. All included parents will, after receiving the participant information, fill out a baseline online questionnaire (including digital informed consent), and will collect a baseline stool sample of their child and save it in the freezer (T0). After that, parents in the intervention groups download and use the app they were assigned to, and all parents report (severity of) URTI symptoms of their child online at 2, 5 and 7 days (T1, T2 and T3) in an online form. Ten days after T0, all parents fill out a follow-up questionnaire, collect a second stool sample from their child, and save it in their own -20 degrees Celsius freezer (T4). At the end of the study, all of the stool samples will be picked up at home by research assistants from UAS Leiden, and will be transferred to Amsterdam University Medical Centre for the laboratory gut microbiome analysis.
Benefits, burden and risks:
The benefit of participating in the study, is that parents in the intervention groups will get extra support by means of the apps, on top of the advices that will be provided by the GP practice. For the control group there is no real benefit, besides contributing to less AB use among children in the future. The burden of this study lies in the fact that parents who participate, will have to fill out two online questionnaires within two weeks, report symptom severity online at two more timepoints, and will have to collect a stool sample of their child twice and save it in the freezer. Parents in the intervention groups will get the advice to download and use one of the two investigated apps. It will be their own decision to actually do this or not.
Participating in the study is safe, because only parents of children with mild, acute, uncomplicated URTIs will be involved. Furthermore, advices/care by the GP practice will be continued for all patients in the study, and the advices in the (self-management) fever app are in line with national fever guidelines. The only difference is that, based on the most recent insights on fever, the app encourages to keep the child warm in the first phase of fever. With regards to safety of the (self-care) DMT App, adverse events due to HM are rare. Moreover, the herbs that are advised on in the app are freely available (without prescription) in drugstores and pharmacies in the Netherlands. Therefore, using the (self-care) DMT App will make things safer rather than less safe, because parents in the HM group will get a trustworthy advice based on scientific evidence and safety regulations, instead of buying herbal medicine without an evidence-based decision-making tool (DMT) like they would normally do.
All participating parents will be advised to always go to the national website with GP advices in case of doubts about the health status of their child, and to call their GP practice, the ED (emergency department) or 112 in case of alarm symptoms. Furthermore, all parents are told to report complications from the URTI and/or adverse events (such as hospitalization) to the researchers. In case of complications or adverse events, they will be will go back to just receiving advices/care from their GP/NP/PA. Participating parents will use the apps in a test account, so no data will be collected by the apps. Also, the online questionnaires they fill out are anonymous, so the privacy of parents who participate is secured. Finally, parents can leave the study at any moment and go back to just receiving advices from their GP practice. There is no relation between (parents in) the different study groups.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- RCT
| Arm | Type | Receives |
|---|---|---|
| FeverApp group | Experimental | Device: FeverAppUse af a self-care FeverApp (containing fever advices and a monitoring function for their child with an uncomplicated URTI), additional to standard advices of the GP. |
| DMT group | Experimental | Device: DMT AppUse of a self-care decision making tool (to choose a herbal medicinal product for their child with an uncomplicated URTI), additional to standard advices from their GP. |
| Control group | No intervention | –Just standard advices from the GP for their child with an uncomplicated URTI. |
Who may qualify
- Ages
- 3 months to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (12 listed)
- Having a child aged 0-12 years old
- Master the Dutch language
- Having called the GP for their child aged 0-12 years having:
- Being screened by a triage specialist (GP practice assistant) and not being indicated for a GP/NP/PA visit
- Not being included in the trial before
Key exclusion criteria (9 listed)
- The current URTI complaints of the child already exist longer than 2 weeks
- The child who has a URTI
- The parent being very worried
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FeverAppThe (self-management) FeverApp contains evidence-based information about fever and how to deal with it, tailored (phase-oriented) fever advices, and the option to monitor the health status of the child during a fever episode. All information and advices are based on the clinical expertise of paediatricians and the most recent international literature on fever, and complement the Dutch national fever guidelines. It is expected that by letting the body fight the infection on its own in a safe way, less ABs are needed, and the immune system will get stronger leading to less future infections as well. | Device | FeverApp group |
| DMT AppThe (self-care) DMT App is a decision making tool (DMT) that can be used by parents to choose a safe and effective herbal medicine (HM) product to reduce symptoms of mild, acute uncomplicated URTIs in their child. The advices that the DMT App provides, are based on a systematic review (SR) of SRs on effectiveness of HM for URTIs, a SR on working mechanisms of the most promising herbs, a prescription rates study of HM for URTIs in 6 European countries, and current EMA status of the included herbs. No prescription from a doctor is needed for these products. | Device | DMT group |
Primary outcome
Antibiotic use (yes/no)
Time frame: Self-reported10 days after inclusion in the study
Antibiotic use of the child in the current URTI episode
7 secondary outcomes
Normal recovery time from URTI
Time frame: Self-reported 10 days after inclusion in the study
Adverse events/complications
Time frame: Self-reported 10 days after inclusion in the study
GP visits
Time frame: Self-reported 10 days after inclusion in the study
Telephone consultations
Time frame: Self-reported 10 days after inclusion in the study
Gut microbiome diversity
Time frame: At baseline (inclusion) AND 10 days after inclusion in the study
AB type
Time frame: Self-reported at 10 days after inclusion in the study
AB dosage
Time frame: Self-reported at 10 days after inclusion in the study
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2023.
- Derived from this study: PubMed 41419287Belt-van Zoen E, van Steenbergen N, Veldman L, Nieuwdorp M, Baars EW. Evaluating the effects of two parental self-management eHealth applications on antibiotic use, number of primary care visits and gut microbiota of febrile Dutch children with acute, uncomplicated upper respiratory tract infections: a study protocol for a randomised controlled trial. BMJ Open. 2025 Dec 19;15(12):e101463. doi: 10.1136/bmjopen-2025-101463.
Related trials for Upper Respiratory Tract Infection
RecruitingPhase 1
A Clinical Trial of V175 and V175A in Healthy Adults
Lower Respiratory Tract Infection
Not yet recruiting
Influence of Patient Positioning During Nasal Lavage
Acute Upper Respiratory Tract Infections, Nasal Obstruction
Recruiting
The Impact of MeMed BV® on Management of Patients With Suspected Lower Respiratory Tract Infections (LRTI) in the Emergency Department (ED) and Urgent Care Center (UCC) ("JUPITER" TRIAL)
Lower Respiratory Tract Infection
RecruitingPhase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Respiratory Tract Diseases, Influenza (Pandemic)
Recruiting
Vocxi Breath Analyzer Study in Pediatric Respiratory Infection
Acute Respiratory Illness, Viral Respiratory Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Max Nieuwdorp, PhD study director
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing FeverApp and DMT App in people with Upper Respiratory Tract Infection, run by Max Nieuwdorp at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Eefje Belt-van Zoen, MSc (+31648134012, belt.e@hsleiden.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Antibiotic use (yes/no) (time frame: Self-reported10 days after inclusion in the study). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06140446, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2023.